These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 37789460

  • 1. Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.
    Tews HC, Elger T, Gunawan S, Fererberger T, Sommersberger S, Loibl J, Huss M, Liebisch G, Müller M, Kandulski A, Buechler C.
    Lipids Health Dis; 2023 Oct 03; 22(1):164. PubMed ID: 37789460
    [Abstract] [Full Text] [Related]

  • 2. Altered fecal bile acid composition in active ulcerative colitis.
    Sommersberger S, Gunawan S, Elger T, Fererberger T, Loibl J, Huss M, Kandulski A, Krautbauer S, Müller M, Liebisch G, Buechler C, Tews HC.
    Lipids Health Dis; 2023 Nov 18; 22(1):199. PubMed ID: 37980492
    [Abstract] [Full Text] [Related]

  • 3. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M, Stroeymeyt K, Kaiserlian D, Drai J, Flourié B.
    Inflamm Bowel Dis; 2013 Apr 18; 19(5):1043-52. PubMed ID: 23511035
    [Abstract] [Full Text] [Related]

  • 4. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P.
    Inflamm Bowel Dis; 2012 Dec 18; 18(12):2218-24. PubMed ID: 22344983
    [Abstract] [Full Text] [Related]

  • 5. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V, Iglesias-Flores E, González R, Gisbert JP, Gallardo-Valverde JM, González-Galilea A, Naranjo-Rodríguez A, de Dios-Vega JF, Muntané J, Gómez-Camacho F.
    J Crohns Colitis; 2010 Jun 18; 4(2):144-52. PubMed ID: 21122498
    [Abstract] [Full Text] [Related]

  • 6. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Ricciuto A, Fish J, Carman N, Walters TD, Church PC, Hansen BE, Crowley E, Siddiqui I, Nguyen GC, Kamath BM, Griffiths AM.
    Clin Gastroenterol Hepatol; 2018 Jul 18; 16(7):1098-1105.e1. PubMed ID: 29378308
    [Abstract] [Full Text] [Related]

  • 7. Fecal short-chain fatty acids in children with inflammatory bowel disease.
    Treem WR, Ahsan N, Shoup M, Hyams JS.
    J Pediatr Gastroenterol Nutr; 1994 Feb 18; 18(2):159-64. PubMed ID: 8014762
    [Abstract] [Full Text] [Related]

  • 8. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T, Yamamoto T, Yoshiyama S, Nishikawa R, Umegae S.
    Inflamm Bowel Dis; 2023 Sep 01; 29(9):1399-1408. PubMed ID: 36334015
    [Abstract] [Full Text] [Related]

  • 9. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease.
    Zhuang X, Li T, Li M, Huang S, Qiu Y, Feng R, Zhang S, Chen M, Xiong L, Zeng Z.
    Inflamm Bowel Dis; 2019 Oct 18; 25(11):1751-1763. PubMed ID: 31498864
    [Abstract] [Full Text] [Related]

  • 10. Short-chain fatty acid levels in stools of patients with inflammatory bowel disease are lower than those in healthy subjects.
    Ozturk O, Celebi G, Duman UG, Kupcuk E, Uyanik M, Sertoglu E.
    Eur J Gastroenterol Hepatol; 2024 Jul 01; 36(7):890-896. PubMed ID: 38829943
    [Abstract] [Full Text] [Related]

  • 11. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease.
    Gauss A, Geiss T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L.
    Medicine (Baltimore); 2016 Apr 01; 95(16):e3477. PubMed ID: 27100452
    [Abstract] [Full Text] [Related]

  • 12. Lyophilized fecal short-chain fatty acid and electrolyte determination by capillary electrophoresis with indirect UV detection for assessment of pediatric inflammatory bowel disease.
    Lemay JA, Yamamoto M, Kroezen Z, Shanmuganathan M, Ly R, Hart L, Pai N, Britz-McKibbin P.
    J Pharm Biomed Anal; 2021 Jan 05; 192():113658. PubMed ID: 33091761
    [Abstract] [Full Text] [Related]

  • 13. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
    Shimizu H, Ebana R, Kudo T, Sato T, Hara T, Hosoi K, Usami M, Yoshida M, Takeuchi I, Nakase H, Iwama I, Arai K, Shimizu T.
    J Gastroenterol; 2022 May 05; 57(5):344-356. PubMed ID: 35165800
    [Abstract] [Full Text] [Related]

  • 14. Urinary soluble CD163 is a putative non-invasive biomarker for primary sclerosing cholangitis.
    Elger T, Fererberger T, Huss M, Sommersberger S, Mester P, Stoeckert P, Gunawan S, Liebisch G, Loibl J, Kandulski A, Müller M, Buechler C, Tews HC.
    Exp Mol Pathol; 2024 Jun 05; 137():104900. PubMed ID: 38729058
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
    Yang Z, Clark N, Park KT.
    Clin Gastroenterol Hepatol; 2014 Feb 05; 12(2):253-62.e2. PubMed ID: 23883663
    [Abstract] [Full Text] [Related]

  • 16. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC, Bachmann Holmetoft U, Ingdam Halkjær S, Angeliki Krogfelt K, Munk Petersen A.
    Scand J Gastroenterol; 2016 Feb 05; 51(2):211-7. PubMed ID: 26359672
    [Abstract] [Full Text] [Related]

  • 17. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
    Palone F, Vitali R, Cucchiara S, Mennini M, Armuzzi A, Pugliese D, DʼIncà R, Barberio B, Stronati L.
    Inflamm Bowel Dis; 2016 Dec 05; 22(12):2886-2893. PubMed ID: 27755215
    [Abstract] [Full Text] [Related]

  • 18. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G.
    World J Gastroenterol; 2017 Nov 07; 23(41):7387-7396. PubMed ID: 29151692
    [Abstract] [Full Text] [Related]

  • 19. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R.
    Inflamm Bowel Dis; 2007 Nov 07; 13(11):1374-8. PubMed ID: 17577247
    [Abstract] [Full Text] [Related]

  • 20. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ, Sydora BC, Fedorak RN.
    J Crohns Colitis; 2012 Mar 07; 6(2):207-14. PubMed ID: 22325175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.